vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and PARK AEROSPACE CORP (PKE). Click either name above to swap in a different company.
PARK AEROSPACE CORP is the larger business by last-quarter revenue ($17.3M vs $10.7M, roughly 1.6× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 17.0%, a 6.5% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 20.3%). Over the past eight quarters, PARK AEROSPACE CORP's revenue compounded faster (3.0% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Park Electrochemical Corp, now called the Park Aerospace Corp, is a Melville, New York-based materials manufacturer for the telecommunications, Internet infrastructure, high-end computing, and aerospace industries. It produces high-technology digital and radio frequency(RF)/microwave printed circuit material products, composite materials. Its printed circuit materials are used for complex multilayer printed circuit boards and other electronic interconnection systems, such as multilayer back-p...
ABUS vs PKE — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $17.3M |
| Net Profit | $2.5M | $3.0M |
| Gross Margin | — | 34.1% |
| Operating Margin | 13.9% | 21.0% |
| Net Margin | 23.5% | 17.0% |
| Revenue YoY | 522.2% | 20.3% |
| Net Profit YoY | 112.7% | 87.1% |
| EPS (diluted) | $0.01 | $0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $17.3M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | $10.7M | $15.4M | ||
| Q1 25 | — | $16.9M | ||
| Q4 24 | — | $14.4M | ||
| Q3 24 | — | $16.7M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $16.3M |
| Q4 25 | — | $3.0M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | $2.5M | $2.1M | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $993.0K | ||
| Q1 24 | — | $2.7M |
| Q4 25 | — | 34.1% | ||
| Q3 25 | — | 31.2% | ||
| Q2 25 | — | 30.6% | ||
| Q1 25 | — | 29.3% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 28.5% | ||
| Q2 24 | — | 29.3% | ||
| Q1 24 | — | 27.3% |
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.4% | ||
| Q2 25 | 13.9% | 15.7% | ||
| Q1 25 | — | 16.8% | ||
| Q4 24 | — | 12.8% | ||
| Q3 24 | — | 15.7% | ||
| Q2 24 | — | 14.9% | ||
| Q1 24 | — | 15.7% |
| Q4 25 | — | 17.0% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | 23.5% | 13.5% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 10.9% | ||
| Q3 24 | — | 12.4% | ||
| Q2 24 | — | 7.1% | ||
| Q1 24 | — | 16.3% |
| Q4 25 | — | $0.15 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | $0.01 | $0.10 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | — | $0.10 | ||
| Q2 24 | — | $0.05 | ||
| Q1 24 | — | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $63.6M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $106.6M |
| Total Assets | $103.3M | $118.1M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $63.6M | ||
| Q3 25 | — | $61.6M | ||
| Q2 25 | $37.4M | $65.6M | ||
| Q1 25 | — | $68.8M | ||
| Q4 24 | — | $70.0M | ||
| Q3 24 | — | $72.0M | ||
| Q2 24 | — | $74.4M | ||
| Q1 24 | — | $77.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $106.6M | ||
| Q3 25 | — | $105.8M | ||
| Q2 25 | $83.0M | $105.0M | ||
| Q1 25 | — | $107.2M | ||
| Q4 24 | — | $107.4M | ||
| Q3 24 | — | $110.3M | ||
| Q2 24 | — | $111.7M | ||
| Q1 24 | — | $112.9M |
| Q4 25 | — | $118.1M | ||
| Q3 25 | — | $116.4M | ||
| Q2 25 | $103.3M | $120.7M | ||
| Q1 25 | — | $122.1M | ||
| Q4 24 | — | $124.2M | ||
| Q3 24 | — | $125.1M | ||
| Q2 24 | — | $129.4M | ||
| Q1 24 | — | $132.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $5.1M |
| Free Cash FlowOCF − Capex | — | $4.3M |
| FCF MarginFCF / Revenue | — | 24.6% |
| Capex IntensityCapex / Revenue | 0.0% | 4.8% |
| Cash ConversionOCF / Net Profit | -6.24× | 1.73× |
| TTM Free Cash FlowTrailing 4 quarters | — | $3.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.1M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | $-15.7M | $1.6M | ||
| Q1 25 | — | $969.0K | ||
| Q4 24 | — | $2.7M | ||
| Q3 24 | — | $1.4M | ||
| Q2 24 | — | $-423.0K | ||
| Q1 24 | — | $5.3M |
| Q4 25 | — | $4.3M | ||
| Q3 25 | — | $-2.3M | ||
| Q2 25 | — | $1.1M | ||
| Q1 25 | — | $338.0K | ||
| Q4 24 | — | $2.7M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $-435.0K | ||
| Q1 24 | — | $5.1M |
| Q4 25 | — | 24.6% | ||
| Q3 25 | — | -14.0% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | — | 18.6% | ||
| Q3 24 | — | 7.5% | ||
| Q2 24 | — | -3.1% | ||
| Q1 24 | — | 31.4% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | 0.0% | 3.1% | ||
| Q1 25 | — | 3.7% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | 1.73× | ||
| Q3 25 | — | -0.88× | ||
| Q2 25 | -6.24× | 0.76× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 1.73× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | -0.43× | ||
| Q1 24 | — | 1.98× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
PKE
| North America | $16.8M | 97% |
| Other | $546.0K | 3% |
